These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 15475447)

  • 1. Matrix metalloproteinase-2 status in stromal fibroblasts, not in tumor cells, is a significant prognostic factor in non-small-cell lung cancer.
    Ishikawa S; Takenaka K; Yanagihara K; Miyahara R; Kawano Y; Otake Y; Hasegawa S; Wada H; Tanaka F
    Clin Cancer Res; 2004 Oct; 10(19):6579-85. PubMed ID: 15475447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of angiogenesis in non-small cell lung cancer: comparison between anti-CD34 antibody and anti-CD105 antibody.
    Tanaka F; Otake Y; Yanagihara K; Kawano Y; Miyahara R; Li M; Yamada T; Hanaoka N; Inui K; Wada H
    Clin Cancer Res; 2001 Nov; 7(11):3410-5. PubMed ID: 11705856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of matrix metalloproteinases and tissue inhibitor of matrix metalloproteinases in non-small-cell lung cancer.
    Suzuki M; Iizasa T; Fujisawa T; Baba M; Yamaguchi Y; Kimura H; Suzuki H
    Invasion Metastasis; 1998-1999; 18(3):134-41. PubMed ID: 10474026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Total cyclooxygenase-2 mRNA levels correlate with vascular endothelial growth factor mRNA levels, tumor angiogenesis and prognosis in non-small cell lung cancer patients.
    Yuan A; Yu CJ; Shun CT; Luh KT; Kuo SH; Lee YC; Yang PC
    Int J Cancer; 2005 Jul; 115(4):545-55. PubMed ID: 15704107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of tissue inhibitor of metalloproteinase-3 (TIMP-3) and its prognostic significance in resected non-small cell lung cancer.
    Mino N; Takenaka K; Sonobe M; Miyahara R; Yanagihara K; Otake Y; Wada H; Tanaka F
    J Surg Oncol; 2007 Mar; 95(3):250-7. PubMed ID: 17323339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of a novel matrix metalloproteinase regulator, RECK, and its clinical significance in resected non-small cell lung cancer.
    Takenaka K; Ishikawa S; Kawano Y; Yanagihara K; Miyahara R; Otake Y; Morioka Y; Takahashi C; Noda M; Wada H; Tanaka F
    Eur J Cancer; 2004 Jul; 40(10):1617-23. PubMed ID: 15196549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased expression of matrix metalloproteinase-2 (MMP-2) predicts tumour recurrence and unfavourable outcome in non-small cell lung cancer.
    Leinonen T; Pirinen R; Böhm J; Johansson R; Kosma VM
    Histol Histopathol; 2008 Jun; 23(6):693-700. PubMed ID: 18366007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor angiogenesis in predicting the survival of patients with stage I lung cancer.
    Medetoglu B; Gunluoglu MZ; Demir A; Melek H; Buyukpinarbasili N; Fener N; Dincer SI
    J Thorac Cardiovasc Surg; 2010 Nov; 140(5):996-1000. PubMed ID: 20708755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Matrix metalloproteinase 9 and the epidermal growth factor signal pathway in operable non-small cell lung cancer.
    Cox G; Jones JL; O'Byrne KJ
    Clin Cancer Res; 2000 Jun; 6(6):2349-55. PubMed ID: 10873086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic impact of MMP-2 and MMP-9 expression in pathologic stage IA non-small cell lung cancer.
    Shao W; Wang W; Xiong XG; Cao C; Yan TD; Chen G; Chen H; Yin W; Liu J; Gu Y; Mo M; He J
    J Surg Oncol; 2011 Dec; 104(7):841-6. PubMed ID: 21721010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer.
    O'Byrne KJ; Koukourakis MI; Giatromanolaki A; Cox G; Turley H; Steward WP; Gatter K; Harris AL
    Br J Cancer; 2000 Apr; 82(8):1427-32. PubMed ID: 10780522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic effect of matrix metalloproteinase-9 in patients with resected Non small cell lung cancer.
    Lee CY; Shim HS; Lee S; Lee JG; Kim DJ; Chung KY
    J Cardiothorac Surg; 2015 Mar; 10():44. PubMed ID: 25888323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pulmonary emphysema and tumor microenvironment in primary lung cancer.
    Murakami J; Ueda K; Sano F; Hayashi M; Nishimoto A; Hamano K
    J Surg Res; 2016 Feb; 200(2):690-7. PubMed ID: 26428090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of matrix metalloproteinase-7 and -9 in NSCLC tumor and stromal cells: correlation with a favorable clinical outcome.
    Stenvold H; Donnem T; Andersen S; Al-Saad S; Al-Shibli K; Busund LT; Bremnes RM
    Lung Cancer; 2012 Feb; 75(2):235-41. PubMed ID: 21764478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation between apoptotic index and angiogenesis in non-small cell lung cancer: comparison between CD105 and CD34 as a marker of angiogenesis.
    Tanaka F; Otake Y; Yanagihara K; Kawano Y; Miyahara R; Li M; Ishikawa S; Wada H
    Lung Cancer; 2003 Mar; 39(3):289-96. PubMed ID: 12609567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated activities of MMP-2 in the non-tumorous lung tissues of curatively resected stage I NSCLC patients are associated with tumor recurrence and a poor survival.
    Kim SH; Choi HY; Lee J; Son DS; Lee HS; Song IS; Lim YS; Hong YS; Kim J; Choi YS
    J Surg Oncol; 2007 Mar; 95(4):337-46. PubMed ID: 17326127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of angiogenetic factors and matrix metalloproteinases upon tumour progression in non-small-cell lung cancer.
    Shou Y; Hirano T; Gong Y; Kato Y; Yoshida K; Ohira T; Ikeda N; Konaka C; Ebihara Y; Zhao F; Kato H
    Br J Cancer; 2001 Nov; 85(11):1706-12. PubMed ID: 11742492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of angiopoietins and its clinical significance in non-small cell lung cancer.
    Tanaka F; Ishikawa S; Yanagihara K; Miyahara R; Kawano Y; Li M; Otake Y; Wada H
    Cancer Res; 2002 Dec; 62(23):7124-9. PubMed ID: 12460935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors in resected pathologic (p-) stage IIIA-N2, non-small-cell lung cancer.
    Tanaka F; Yanagihara K; Otake Y; Kawano Y; Miyahara R; Takenaka K; Katakura H; Ishikawa S; Ito H; Wada H
    Ann Surg Oncol; 2004 Jun; 11(6):612-8. PubMed ID: 15150069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of MDA-7/IL-24 and its clinical significance in resected non-small cell lung cancer.
    Ishikawa S; Nakagawa T; Miyahara R; Kawano Y; Takenaka K; Yanagihara K; Otake Y; Katakura H; Wada H; Tanaka F
    Clin Cancer Res; 2005 Feb; 11(3):1198-202. PubMed ID: 15709189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.